Table 1 Characteristics of 6 Trials on pentoxifylline in subjects with NAFLD
Source | Methodological quality | Diagnosis | Pentoxifylline/Control (numbers) | Interventions | Outcome | |
|---|---|---|---|---|---|---|
Pentoxifylline | Control | |||||
LeeYin-Mei, 2008[20] | Randomized and placebo-controled | NASH | 11/9 | Pentoxifylline (1200 mg/day for 12 weeks) plus low-calorie diet and daily exercise | Placebo plus low-calorie diet and daily exercise | AST, ALT, IL-6, TNF-a, adverse events |
Buranawati W, 2007[21] | Randomized and placebo-controled | NASH | 16/16 | Pentoxifylline (1200 mg/day for 12 weeks) plus low-calorie diet | Placebo plus low-calorie diet | AST, ALT, TNF-a |
Tuncer I, 2003[22] | Prospective cohort study with concurrent control | NAFLD | 10/10 | pentoxifylline (20 mg/kg/day for 24 weeks) | ursodeoxycholic acid | AST, ALT |
Georgescu, EF 2007[23] | Prospective cohort study with concurrent control | NASH | 13/13 | Pentoxifylline (800 mg/day for 30 weeks) | Ursodeoxycholic acid | ALT, IL-6, TNF-a, Histology |
Adams 2004[24] | Prospective cohort study with historical control | NASH | 20 | Pentoxifylline (1,600 mg/day) for 12 months | Adverse events | |
Satapathy SK 2007 [25] | Prospective cohort study with historical control | NASH | 9 | Pentoxifylline (1200 mg/day for 12 months) | Histology |